0JBU.L

Intellia Therapeutics, Inc. [0JBU.L] Stock Forecast

Q: What is Intellia Therapeutics, Inc. stock symbol ?

Intellia Therapeutics, Inc. is a US stock, located in Cambridge of Ma and trading under the symbol 0JBU.L

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

0JBU.L Stock Summary

Earnings are expected to rise 4894.53% next year

0JBU.L has less than 1 year of cash runway

Top 10 Correlated ETFs

0JBU.L

Top 10 Correlated Stocks

0JBU.L

In the News

0JBU.L Financial details

Company Rating

Sell

Market Cap

2.34B

Income

-481.19M

Revenue

36.28M

Book val./share

11.61

Cash/share

10.08

Dividend

Dividend %

Employees

526

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

-5.62

Forward P/E

-4.05

PEG

4.62

P/S

50.76

P/B

2.5

P/C

2.27

P/FCF

-6.45

Quick Ratio

9.37

Current Ratio

9.72

Debt / Equity

0.02

LT Debt / Equity

EPS (TTM)

-5.41

EPS next Y

-5.64

EPS next Q

-1.29

EPS this Y

-12.01%

EPS next Y

4.21%

EPS next 5Y

-204.67%

EPS last 5Y

20.77%

Revenue last 5Y

-3.39%

Revenue Q/Q

-115.99%

EPS Q/Q

5.8%

SMA20

-15.06%

SMA50

-0.92%

SMA100

-5.51%

Inst Own

Inst Trans

ROA

-37%

ROE

-40%

ROC

-0.42%

Gross Margin

-723%

Oper. Margin

-938%

Profit Margin

-893%

Payout

Shs Outstand

96.11M

Shs Float

93.89M

Target Price

52W Range

22.69-46.91

52W High

-50.28%

52W Low

+3.95%

RSI

32.43

Rel Volume

0.93

Avg Volume

3.14K

Volume

2.91K

Perf Week

-8.85%

Perf Month

-29.09%

Perf Quarter

-16.1%

Perf Half Y

-23.1%

Beta

1.798

Volatility

0.92%, 2.42%

Prev Close

-6.27%

Price

22.87

Change

-7.52%

0JBU.L Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.91	1.04	0.47	0.68	0.41
Net income per share	-2.11	-2.4	-3.78	-6.16	-5.42
Operating cash flow per share	-2.19	-0.89	-3.17	-4.33	-4.44
Free cash flow per share	-2.33	-0.96	-3.35	-4.51	-4.6
Cash per share	5.92	10.72	10.56	15.49	10.28
Book value per share	5.71	9.41	14.67	16.05	11.83
Tangible book value per share	5.71	9.41	14.67	16.05	11.83
Share holders equity per share	5.71	9.41	14.67	16.05	11.83
Interest debt per share	0.12	0.1	0.13	0.22	0.21
Market cap	4.55B	5.39B	6.82B	2.64B	2.72B
Enterprise value	4.51B	5.26B	6.77B	2.25B	2.61B
P/E ratio	-45.67	-40.13	-25.46	-5.57	-5.66
Price to sales ratio	105.47	92.89	206.38	50.67	75.08
POCF ratio	-44.03	-107.93	-30.31	-7.92	-6.91
PFCF ratio	-41.32	-100.7	-28.69	-7.61	-6.67
P/B Ratio	16.84	10.22	6.56	2.14	2.59
PTB ratio	16.84	10.22	6.56	2.14	2.59
EV to sales	104.57	90.76	204.88	43.13	72.01
Enterprise value over EBITDA	-44.72	-40.41	-25.95	-4.99	-5.16
EV to operating cash flow	-43.66	-105.46	-30.09	-6.75	-6.63
EV to free cash flow	-40.96	-98.39	-28.48	-6.48	-6.4
Earnings yield	-0.02	-0.02	-0.04	-0.18	-0.18
Free cash flow yield	-0.02	-0.01	-0.03	-0.13	-0.15
Debt to equity	0.02	0.01	0.01	0.01	0.02
Debt to assets	0.02	0.01	0.01	0.01	0.01
Net debt to EBITDA	0.39	0.95	0.19	0.87	0.22
Current ratio	8.12	9.59	6.11	9.61	8.67
Interest coverage	0	0	0	0	0
Income quality	1.04	0.37	0.84	0.7	0.82
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.95	0.76	2.15	1.73	0
Research and developement to revenue	2.52	2.48	6.74	7.91	11.75
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.07	0.07	0.06	0.04	0.04
Capex to revenue	-0.16	-0.06	-0.39	-0.26	-0.39
Capex to depreciation	-1.22	-0.57	-1.85	-1.79	-1.56
Stock based compensation to revenue	0.35	0.34	1.42	1.75	0
Graham number	16.45	22.54	35.32	47.17	37.99
ROIC	-0.37	-0.24	-0.24	-0.34	-0.44
Return on tangible assets	-0.3	-0.2	-0.21	-0.31	-0.37
Graham Net	4.63	8.08	7	11.83	7.76
Working capital	253.85M	552.26M	643.47M	1.09B	883.12M
Tangible asset value	269.88M	527.07M	1.04B	1.24B	1.05B
Net current asset value	225.08M	467.27M	515.08M	932.27M	747.52M
Invested capital	0.02	0.01	0.01	0.01	0.02
Average receivables	6.08M	3.38M	2.08M	2.9M	20.11M
Average payables	3.32M	7.2M	10.06M	7.4M	6.3M
Average inventory	1	0.5	0.5	0.5	0
Days sales outstanding	39.12	13.41	22.43	26.39	366.82
Days payables outstanding	13.27	25.38	511.3	248.44	303.03
Days of inventory on hand	0	0	0	0	0
Receivables turnover	9.33	27.23	16.27	13.83	1
Payables turnover	27.51	14.38	0.71	1.47	1.2
Inventory turnover	108.41M	0	6.89M	0	0
ROE	-0.37	-0.25	-0.26	-0.38	-0.46
Capex per share	-0.14	-0.06	-0.18	-0.18	-0.16

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.17	0.14	0.15	0.14	-0.02
Net income per share	-1.4	-1.17	-1.4	-1.38	-1.46
Operating cash flow per share	-1.11	-1.25	-1.02	-1.14	-1.03
Free cash flow per share	-1.15	-1.29	-1.07	-1.19	-1.05
Cash per share	14.68	10.64	10.3	9.64	10.08
Book value per share	15.21	13.57	12.53	11.7	11.61
Tangible book value per share	15.21	13.57	12.53	11.7	11.61
Share holders equity per share	15.21	13.57	12.53	11.7	11.61
Interest debt per share	0.21	0.19	0.19	0.19	0.21
Market cap	2.79B	3.24B	3.6B	2.8B	2.78B
Enterprise value	2.39B	3.07B	3.55B	2.75B	2.66B
P/E ratio	-6.14	-7.86	-7.28	-5.72	-5.25
Price to sales ratio	205.32	257.06	264.87	233.29	-1.45K
POCF ratio	-31.01	-29.64	-39.86	-27.6	-29.83
PFCF ratio	-29.72	-28.64	-38.05	-26.46	-29.35
P/B Ratio	2.26	2.72	3.26	2.7	2.64
PTB ratio	2.26	2.72	3.26	2.7	2.64
EV to sales	176.38	243.73	261.23	229.15	-1.39K
Enterprise value over EBITDA	-22.15	-27.96	-27.28	-21.33	-19.38
EV to operating cash flow	-26.64	-28.1	-39.32	-27.11	-28.63
EV to free cash flow	-25.53	-27.15	-37.53	-25.99	-28.17
Earnings yield	-0.04	-0.03	-0.03	-0.04	-0.05
Free cash flow yield	-0.03	-0.03	-0.03	-0.04	-0.03
Debt to equity	0.01	0.01	0.02	0.02	0.02
Debt to assets	0.01	0.01	0.01	0.01	0.01
Net debt to EBITDA	3.64	1.53	0.38	0.39	0.81
Current ratio	9.61	9.32	9.41	9.72	8.67
Interest coverage	0	0	0	0	0
Income quality	0.79	1.06	0.73	0.83	0.7
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.74	2.18	2.25	2.45	0
Research and developement to revenue	7.22	7.54	8.32	9.29	-55.56
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.04	0.04	0.05	0.04	0.02
Capex to revenue	-0.29	-0.3	-0.32	-0.36	0.79
Capex to depreciation	-1.93	-1.87	-1.98	-1.89	-0.62
Stock based compensation to revenue	1.81	2.16	2.68	2.95	0
Graham number	21.86	18.94	19.88	19.05	19.53
ROIC	-0.08	-0.09	-0.11	-0.11	-0.12
Return on tangible assets	-0.07	-0.07	-0.09	-0.1	-0.1
Graham Net	11.22	8.09	7.86	7.37	7.61
Working capital	1.09B	860.29M	839.76M	801.54M	883.12M
Tangible asset value	1.24B	1.19B	1.1B	1.04B	1.05B
Net current asset value	932.27M	736.63M	721.26M	687.56M	747.52M
Invested capital	0.01	0.01	0.02	0.02	0.02
Average receivables	3.9M	4.34M	4.98M	5.77M	21.47M
Average payables	4.77M	6.02M	9.26M	7.59M	5.5M
Average inventory	0.5	0	0.5	0.5	0
Days sales outstanding	24.98	35.03	33.47	48.71	-1.71K
Days payables outstanding	228.39	302.49	482.52	139.64	271.97
Days of inventory on hand	0	0	0	0	0
Receivables turnover	3.6	2.57	2.69	1.85	-0.05
Payables turnover	0.39	0.3	0.19	0.64	0.33
Inventory turnover	0	0	2.17M	0	0
ROE	-0.09	-0.09	-0.11	-0.12	-0.13
Capex per share	-0.05	-0.04	-0.05	-0.05	-0.02

0JBU.L Frequently Asked Questions

What is Intellia Therapeutics, Inc. stock symbol ?

Intellia Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol 0JBU.L

What is Intellia Therapeutics, Inc. stock quote today ?

Intellia Therapeutics, Inc. stock price is $22.87 today.

Is Intellia Therapeutics, Inc. stock public?

Yes, Intellia Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 3.14K
Market Capitalization 2.34B
Employee 526
CEO Dr. John M. Leonard M.D.
Headquarters Cambridge,MA,US
IPO Date 2018-01-29
Website https://www.intelliatx.com

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.